We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Suit Cools Patients

By HospiMedica staff writers
Posted on 01 Dec 2006
A new thermal-regulating system helps accomplish temperature reduction and monitoring in hyperthermic patients. More...


The ThermoSuit cools the body by providing a thin layer of rapidly flowing liquid coolant in direct contact with the skin. The system consists of a disposable body suit, a multilumen umbilicus hose that connects the body enclosure to a pump assembly (pump drive units and reservoir bag), and a pump controller console with touchscreen display. Hyperthermic patients are placed into the mattress of the body suit, which conforms to their shape and size upon inflation. A polyurethane top sheet is attached to the rim of the inflated suit via Velcro strips and covers the patient to neck level.

A target temperature is entered on the touch screen for initiation of cooling therapy. Both body suit components feature built-in flow channels that allow water to be pumped against the patient's skin for heat exchange. Cold water is allowed to circulate through the top and bottom of the body suit and drip onto the patient before its return through the mattress' porous lining to the water reservoir.

The temperature of patients undergoing therapy can be monitored using an attached esophageal or nasopharyngeal temperature probe. Once the target temperature has been reached, an alert is sounded before water is purged from the body suit. Water can also be purged by manual control.

The ThermoSuit is a product of Life Recovery Systems (Alexandria, LA, USA).

The American Heart Association (AHA) recommends that unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest should be cooled to 32- 34°C for 12-24 hours when the initial rhythm was ventricular fibrillation. Such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest.



Related Links:
Life Recovery Systems

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.